|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Primary Brain Cancer - Temozolomide Turns Heads
Datamonitor, July 2005, Pages: 144
Introduction
The incidence of glioblastoma is increasing. Schering-Ploughs temozolomide has gained approval as first line therapy for glioblastoma and has provided some survival benefit. However, median survival is still a modest fifteen months. Thus, the glioblastoma market is characterized by a high level of unmet need and consequently lucrative commercial value.
Scope
Overview of disease including epidemiology, biology of glioma and prognostic variables
Current treatment options and clinical controversies including comments from opinion leaders
Key recommendations in the areas of greatest unmet need in glioblastoma patients
Profiles of agents in late stage development including opinions from glioma specialists
Highlights
Temozolomides approval as first line therapy for glioblastoma is a significant advance for these patients. The surge in US sales since its March 2005 approval reflects the current dearth in effective therapy for these patients. Temozolomide has raised the bar for other agents and, as such, physician expectation is now higher
Peregrines Cotara is in late stage development for glioblastoma. However, we believe that Cotaras cumbersome administration and low physician awareness may hinder uptake
Opinion leaders feel the future for glioblastoma treatment will focus on novel targeted treatments. Eli Lillys enzastaurin has demonstrated a 20% response rate in heavily pre-treated patients in Phase II trials, and may be the most promising early developmental agent at present. Phase III trials are planned combining enzastaurin with temozolomide
Reasons to Purchase
Understand the limitations of current therapy available to glioma patients and the potential of future therapy
Identify future market opportunities based on opinion leader comments regarding unmet needs, marketed products and those in the pipeline
Plan new product development based on an understanding of physician expectation for improvements in survival, quality of life and economic constraints
Customers who bought this item also bought
Stakeholder Opinions: Primary Brain Cancer
Glioblastoma Review - Temodar partnering pipeline drugs
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Stakeholder Opinions: Brain Metastases - Turning Prolonged Survival on its Head?
Glioblastoma - Is There life After Temodar?
Niche Cancers 2001: Glioblastoma
Cancer - Brain Tumor
Prostate Cancer Opinion Leader Forum, 2002
Cell Therapy - Technologies, Markets and Companies
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Cancer Cell Therapy Markets
Brain metastases
|
|
|
|
